Alpha-ketoglutarate sits at a metabolic crossroads. It is an intermediate of the Krebs cycle and the obligate co-substrate for TET1/2/3 enzymes (which demethylate DNA) and Jumonji-domain histone demethylases. When AKG levels drop, these enzymes slow down, and the epigenetic landscape drifts. DNA becomes hypermethylated at specific CpG sites. The biological age clocks register the result.

AKG levels decline significantly with age. Chin et al. (2014) measured plasma metabolites across age groups and found that circulating AKG drops by roughly 10-fold between ages 40 and 80. This decline correlates with reduced TET enzyme activity and the classic epigenetic drift measured by Horvath and GrimAge clocks.

The preclinical data came first. Asadi Shahmirzadi et al. published in Cell Metabolism in 2020, showing that AKG supplementation in aged mice reduced frailty scores, improved fur quality, decreased chronic inflammation, and compressed morbidity. The median lifespan was not significantly extended, but healthspan was — the treated mice were healthier for longer before dying.

The human trial, published by Demidenko et al. in Aging in 2021, tested calcium alpha-ketoglutarate at 1,000 mg/day in 42 adults aged 45–65 for seven months. Biological age was assessed using the Horvath, Hannum, and PhenoAge DNA methylation clocks. Participants showed a mean reduction of 8 years in biological age across all three clocks. The effect was most pronounced in participants whose biological age exceeded their chronological age at baseline.

The trial has important limitations. It was open-label with no placebo control, meaning expectation effects cannot be ruled out. The sample size was small. No functional outcomes were measured. A randomized, placebo-controlled follow-up with functional endpoints is needed to confirm these findings.

The mechanism is biologically plausible. TET enzymes require AKG to catalyze the oxidation of 5-methylcytosine to 5-hydroxymethylcytosine, the first step in active DNA demethylation. By restoring AKG levels, the intervention may reactivate TET-mediated demethylation at age-associated CpG sites, directly reversing the methylation changes that biological age clocks detect.

Brian Kennedy at the National University of Singapore has called AKG one of the most promising geroprotective candidates because it sits at the intersection of energy metabolism and epigenetic regulation. Unlike rapamycin or metformin, which act on signaling pathways, AKG supplies a substrate directly consumed by epigenetic maintenance enzymes.

CaAKG supplements are available over the counter at $30–$60/month. The compound has a long safety record and is FDA-classified as GRAS. The data is preliminary, but the cost and risk are low enough that many longevity clinicians have adopted it as part of their geroprotective stacks while awaiting rigorous trial data.